Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cell therapy
Biotech
Vor Bio's dual stem cell, ADC shows consistent engraftment
Vor Bio plans to accelerate enrollment of a phase 1/2 trial of its dual stem cell-ADC cancer therapy to get a fuller picture of post-relapse response.
Max Bayer
Nov 9, 2023 4:10pm
Atara's stock sinks as MS cell therapy fails in phase 2
Nov 9, 2023 6:50am
Senti, Celest take cell therapy to China in $156M deal
Nov 7, 2023 10:15am
Cell therapy allows kidney recipients to cut immunosuppressants
Nov 2, 2023 10:00am
BrainStorm lays off 30%, details bid to reach ALS market
Oct 24, 2023 9:17am
Athersys nears bankruptcy as cell therapy fails interim analysis
Oct 10, 2023 10:50am
